← Leaderboards
Rebecca Dawn Hodge
Allen Institute
$4,389,071
Attributed
$4,389,071
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.1M · FY2020–25$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,583,402 · 2
By mechanism
U19$59,583,402 · 2
Top collaborators
- Jennie Leigh Close6 shared
- Michael Hawrylycz6 shared
- Christopher D Keene6 shared
- Ed Lein6 shared
- Jeremy Miller4 shared
Most similar at Allen Institute
Same institution · by research overlap
- Ed Lein$107,008,589
- Michael Hawrylycz$19,903,296
- Hongkui Zeng$119,941,079
- Jack Waters$6,650,539
- Bosiljka Tasic$16,079,397
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposS Disease PathologyGenomicsS DiseaseCommunitiesTranscriptomicsMolecular ProfilingMolecularPathologyResolutionS Disease BrainEpigenomicsAffectDisorder SubtypeCell TypeCell NucleusCellsBrainData SetNeuropathologyResistanceCohortEpigenetic ProcessAutopsy
Grant awards (7)
A multimodal brain cell atlas and community resource of Alzheimer's disease and comorbid dementias.$14,713,224
U19 · FY2025 · AG
Single cell multiomic characterization of the diverse spectrum of Alzheimer's disease across the brain.$4,389,071
U19 · FY2025 · AG · contact PI
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease$6,063,410
U19 · FY2024 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease$9,555,451
U19 · FY2023 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease$9,590,782
U19 · FY2022 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease$8,272,985
U19 · FY2021 · AG
A platform for cell type-level transcriptomic, epigenomic and spatial interrogation of Alzheimer's disease$6,998,479
U19 · FY2020 · AG